Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24136447 | 1.00 | GRIN2B (0.45) | GRIN2BGRIN1ESR1ESR2KMT2A | |
| SCHEMBL21864454 | 0.84 | KMT2A (0.53) | GRIN2BKMT2A | |
| SCHEMBL18629683 | 0.83 | GRIN2B (0.50) | GRIN2BGRIN1 | |
| SCHEMBL18629406 | 0.83 | GRIN2B (0.53) | GRIN2BGRIN1 | |
| SCHEMBL24136436 | 0.83 | ESR1 (0.46) | GRIN2BGRIN1ESR1ESR2 | |
| SCHEMBL22239314 | 0.83 | GRIN2B (0.63) | GRIN2BGRIN1 | |
| SCHEMBL24136379 | 0.83 | GRIN2B (0.63) | GRIN2BGRIN1 | |
| SCHEMBL24136355 | 0.81 | GRIN2B (0.45) | GRIN2BGRIN1 | |
| SCHEMBL24136435 | 0.81 | GRIN2B (0.45) | GRIN2BGRIN1 | |
| SCHEMBL24136424 | 0.81 | GRIN2B (0.45) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239835-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B | CADENT THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180111902-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | LUC THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111902-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | OXER1, OPRL1, OXGR1 | GRIN2B 25/4885GRIN1 31/4885ESR1 1327/4885 |
| US-10239835-B2 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B | OXER1, OPRL1, OXGR1 | GRIN2B 25/4885GRIN1 31/4885ESR1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.